Form 4: Femasys CFO Acquires Warrants in Private Placement

Femasys Inc.'s Chief Financial Officer, Dov Elefant, acquired 34,122 Series D-1 Warrants with an exercise price of $0.58 per share as part of an Omnibus Amendment and Consent Agreement.

Summary

• Dov Elefant, Chief Financial Officer of Femasys Inc. (FEMY), acquired 34,122 Series D-1 Warrants.
• The warrants have an initial exercise price of $0.58 per share of common stock.
• They are exercisable starting March 19, 2026, and expire on March 19, 2036.
• The acquisition was part of a private placement as consideration for an Omnibus Amendment and Consent Agreement dated March 19, 2026.
• The exercise of these warrants is subject to Nasdaq Capital Market rules and standard adjustments for corporate actions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it aligns the CFO's interests with long-term shareholder value, though potential dilution is a minor concern.

Positives

• The CFO's acquisition of warrants indicates a potential alignment of interests with shareholders, as the warrants gain value if the stock price rises above the exercise price.
• The issuance of warrants as consideration in an agreement suggests a non-cash component to a transaction, potentially preserving company cash.

Negatives

• The issuance of warrants could lead to dilution if exercised, increasing the number of outstanding shares.
• The specific terms of the Omnibus Amendment and Consent Agreement are not detailed, making a full assessment of the consideration difficult.

Risks

• Potential future dilution for existing shareholders if the 34,122 Series D-1 Warrants are exercised.
• The exercise price of $0.58 per share may be below the current market price, making exercise more likely and increasing dilution risk.
• The ability to exercise is subject to Nasdaq Capital Market rules, which could impose unforeseen restrictions.

Future Outlook

The warrants are exercisable over a ten-year period, indicating a long-term incentive for the CFO tied to the company's future stock performance.

Management Comments

• The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026.

Industry Context

StockSavvy.ai notes that the issuance of warrants to executives is a common practice in the biotechnology and medical device sectors, particularly for smaller or growth-stage companies like Femasys, as it provides long-term incentives and can conserve cash. This aligns executive compensation with shareholder value creation over time.

Comparison to Industry Standards

• Issuing warrants as part of executive compensation or as consideration in agreements is a standard practice, particularly in industries where cash flow management is critical, such as early-stage biotech or medical device companies. For example, similar structures have been observed in companies like Inovio Pharmaceuticals (INO) or Aeterna Zentaris (AEZS) where warrants are used to incentivize management or secure financing without immediate cash outlay.
• The exercise price of $0.58 per share should be evaluated against Femasys's current stock price and peer valuations to determine if it represents a significant premium or discount, which is typical for incentive-based warrants.

Related Party Transactions

• The issuance of warrants to the Chief Financial Officer as consideration in an agreement constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but also potential for increased management alignment with shareholder interests.
• Management (CFO): Receives a long-term incentive tied to the company's stock performance.

Next Steps

• Monitoring of Femasys Inc.'s stock price relative to the warrant exercise price of $0.58.
• Future disclosures regarding the Omnibus Amendment and Consent Agreement may provide more context.
• Potential future Form 4 filings if the warrants are exercised or disposed of.

Key Dates

Recommendation

The acquisition of warrants by the CFO is a standard insider transaction that aligns management incentives with long-term company performance. While it introduces potential future dilution, it does not fundamentally alter the company's financial or operational outlook in a way that warrants a strong buy or sell recommendation based solely on this filing. Investors should hold and monitor broader company performance and market conditions.

Keywords

Femasys, FEMY, Dov Elefant, CFO, Warrants, Series D-1 Warrants, Private Placement, Omnibus Amendment, Beneficial Ownership, Insider Trading, SEC Form 4